
|Videos|May 14, 2014
The Current State of the Treatment of Kidney Cancer
Author(s)James J. Hsieh, MD, PhD
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, provides an overview of the treatment of kidney cancer.
Advertisement
Clinical Pearls
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, provides an overview of the treatment of kidney cancer.
- The treatment of kidney cancer can be divided into two categories: anti-angiogenic therapies and mTOR inhibitors.
- Before 2007, the main treatment options were interferon and interleukin-2.
- Many drugs have been approved since 2007, including sorafenib, axitinib, sunitinib, pazopanib, bevacizumab, temsirolimus, and everolimus.
- About 75-80% of patients with kidney cancer have clear cell-type disease.
- Today, no standard of care exists for rare types of kidney cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5








































